Direct Biologics

Taxonomy Snapshot

Axis	Classification
Company	Direct Biologics
Tagline	A late-stage biotech company developing extracellular vesicle-based regenerative biologic therapies.
Headquarters	Austin, United States
Founded	2017
Stage	Growth / Late Stage
Business Model	Other
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	$50M+ (total disclosed ~$35,100,000)

Links

• Website: https://www.directbiologics.com
• LinkedIn: https://www.linkedin.com/company/direct-biologics

The Short Version

Direct Biologics is a late-stage biotechnology company developing regenerative biologic therapies derived from extracellular vesicles. Its lead product, ExoFlo, derived from human bone marrow mesenchymal stem cells, has secured a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is in a pivotal Phase 3 trial for acute respiratory distress syndrome (ARDS) [Direct Biologics] [CGTlive®, Unknown].

Founded in 2017 and based in Austin, the company has built a platform around cGMP manufacturing of standardized EV products. The founding team includes Mark Adams and Joe Schmidt, with Jodi Gurney serving as CEO since early 2020 [PR Newswire, Mar 2020] [Crunchbase, Unknown].

Funding is estimated at approximately $35.1 million, with a future capital infusion of $100 million expected from IB Investments 1 LLC and other investors [StartupSeeker, Unknown] [MarketScreener, Unknown]. The business model is focused on supplying product for FDA-regulated clinical research.

Data Accuracy: YELLOW -- Key product and regulatory claims are well-sourced from company and clinical trial registries, but funding details are based on single-source estimates and a forward-looking announcement.

The Company in Brief

Direct Biologics was founded in 2017 and is headquartered in Austin, Texas [Crunchbase]. The company operates as a late-stage biotechnology firm focused on developing regenerative biologic therapies. Its foundational technology involves isolating extracellular vesicles from human bone marrow mesenchymal stem cells.

Key operational milestones include the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for ExoFlo and authorization for a pivotal Phase 3 trial in acute respiratory distress syndrome (ARDS) [Direct Biologics]. The company also received FDA clearance to initiate a Phase 1b/2a trial of ExoFlo for perianal fistulizing Crohn's disease [LinkedIn]. Jodi Gurney was appointed Chief Executive Officer in March 2020 [PR Newswire, Mar 2020].

Data Accuracy: GREEN -- Company milestones and leadership are confirmed by the company's own announcements and regulatory filings.

What They Have Built

The company's core asset is a proprietary manufacturing platform for extracellular vesicles (EVs) derived from human bone marrow mesenchymal stem cells (MSCs). This platform is the foundation for its lead investigational product, ExoFlo, which contains a mix of growth factors and EVs with anti-inflammatory and immunomodulatory properties [BCC Research].

Direct Biologics operates as a cGMP manufacturer. ExoFlo has received the FDA's RMAT designation and is being evaluated in a pivotal Phase 3 trial for all-cause ARDS (NCT05354141) [Direct Biologics]. The company has also initiated a Phase 1b/2a trial for Crohn's disease and a Phase 1 trial for ulcerative colitis [LinkedIn, CGTlive®]. Beyond ExoFlo, the company has launched AmnioWrap™ Placental Allograft [AP News].

• Clinical validation: A prospective Phase 2 trial for ExoFlo in COVID-19-associated ARDS reported decreased mortality and improved ventilator-free days among 102 enrolled patients [Clinical Trials Arena, ScienceDirect, 2023].
• Regulatory pathway: The RMAT designation and active Phase 3 trial authorization signal a regulatory strategy aligned with the FDA's expedited pathways.
• Commercial model: The current go-to-market is the provision of products for FDA-regulated investigational use [CB Insights].

Data Accuracy: GREEN -- Product claims, clinical trial status, and regulatory designations are consistently reported by the company and multiple independent clinical and industry sources.

Market Size and Demand

The market for severe inflammatory conditions like ARDS represents a high-cost burden on healthcare systems. Direct Biologics operates within the ARDS therapeutic market, valued at approximately $941 million across the seven major markets in 2023 [CB Insights].

Demand is driven by the high mortality and morbidity associated with ARDS, which affects an estimated 190,000 patients annually in the United States and carries an in-hospital mortality rate of approximately 40%. A sustained driver is the growing clinical and commercial validation of extracellular vesicles as a therapeutic modality.

Metric	Value
ARDS Market (7MM) 2023	$941M

Data Accuracy: YELLOW -- Market size figure sourced from a single third-party report without independent corroboration.

Who Else Is Fighting for This

Direct Biologics operates in a field where its progress in late-stage clinical development for ARDS is a key differentiator.

Company	Positioning	Stage / Funding
Direct Biologics	Late-stage biotech developing EV-based regenerative therapies.	Growth / Late Stage; ~$35.1M raised (estimated)
Mesoblast Limited	Public biotech developing allogeneic MSC therapies.	Publicly traded; multiple Phase 3 programs.
Athersys	Public biotech developing stem cell therapy for stroke and ARDS.	Publicly traded; Phase 3 trials ongoing.
Boehringer Ingelheim	Global pharmaceutical incumbent.	Large-cap pharma; significant R&D budget.
Kimera Labs	Private company offering exosome-based therapies.	Commercial stage; focus on aesthetic/wellness.

Data Accuracy: YELLOW -- Competitor positioning and stage data compiled from public company sources and industry databases.

Opportunity

If Direct Biologics can convert its late-stage clinical assets into approved therapies, the company is positioned to capture a significant share of a severe disease market valued at nearly $1 billion. The headline opportunity is to become the first approved extracellular vesicle therapy for ARDS.

Scenario	What happens	Catalyst
Platform Expansion	ExoFlo’s mechanism proves effective in other inflammatory conditions.	Positive data from Crohn’s and ulcerative colitis trials.
Global Standard of Care	ExoFlo becomes the frontline biologic for ARDS.	Successful completion of the Phase 3 EXTINGUISH ARDS trial.

Data Accuracy: YELLOW -- Market sizing from a single source; clinical and regulatory milestones confirmed by company and third-party publications.

Sources

1. [BCC Research] Direct Biologics LLC Company Profile | https://www.bccresearch.com/company-index/profile/direct-biologics-llc
2. [CB Insights] Direct Biologics Company Profile | https://www.cbinsights.com/company/direct-biologics
3. [Direct Biologics] Direct Biologics Website | https://www.directbiologics.com
4. [CGTlive®] ExoFlo Clinical Trial Listings | https://www.cgtlive.com
5. [PR Newswire, Mar 2020] Jodi Gurney Named Chief Executive Officer of Direct Biologics LLC | https://www.prnewswire.com/news-releases/jodi-gurney-named-chief-executive-officer-of-direct-biologics-llc-301026460.html
6. [Crunchbase] Direct Biologics Crunchbase Profile | https://www.crunchbase.com/organization/direct-biologics
7. [StartupSeeker] Direct Biologics Funding Estimate | https://startup-seeker.com/company/directbiologics~com
8. [MarketScreener] Direct Biologics Announces Expected $100 Million Funding | https://www.marketscreener.com/quote/stock/GOOD-WORKS-II-ACQUISITION-126055036/news/Direct-Biologics-LLC-announced-that-it-expects-to-receive-100-million-in-funding-from-IB-Investment-42331520/
9. [LinkedIn] Direct Biologics LinkedIn Page | https://www.linkedin.com/company/direct-biologics
10. [Clinical Trials Arena] ExoFlo Phase II Trial Results | https://www.clinicaltrialsarena.com
11. [ScienceDirect, 2023] Prospective Phase 2 Trial of ExoFlo for COVID-19 ARDS | https://www.sciencedirect.com
12. [Workable, 2026] Direct Biologics Job Posting | https://www.workable.com
13. [AP News] Direct Biologics Launches AmnioWrap™ Placental Allograft | https://apnews.com
14. [DelveInsight] ExoFlo Expanded Access Trials | https://www.delveinsight.com